Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
نویسندگان
چکیده
Tobramycin powder for inhalation (TOBI Podhaler or TIP) is approved for the treatment of Pseudomonas aeruginosa airway infection in patients with cystic fibrosis (CF). A population pharmacokinetic model for tobramycin inhalation powder (TIP) in CF patients was developed to characterize the effect of covariates including body mass index (BMI) and lung function (forced expiratory volume in 1 s as percent of the predicted value (FEV1% predicted) at baseline) on the serum exposure parameters.A two-compartment model with first-order elimination and first-order absorption was developed. Across a range of baseline demographic values in the study population, the predicted mean values for the maximum (Cmax) and trough (Ctrough) plasma concentrations at steady state were at least 7.5 and 5-fold lower, respectively, than the recommended thresholds for tobramycin toxicity (12 µg/ml for Cmax and 2 µg/ml for Ctrough). This model adequately described the tobramycin serum concentration-time course in CF patients following inhalation of TIP. The results indicate that no BMI- or FEV1-based dose adjustment is needed for use of TIP in CF patients.
منابع مشابه
IN THIS ISSUE COMMENTARY Comparing Inhaled Aztreonam to Tobramycin Cost Effectiveness of Aztreonam Lysine Inhaled Tobramycin Affected by Chronic Azithromycin Use AZLI Use: Three Year Prevalence Changes Comparing Colistimethate Sodium Dry Powder to Inhaled Tobramycin Program Directors
Pseudomonas aeruginosa colonization of the cystic fibrosis airway requires chronic therapy with inhaled antibiotics for nearly all patients. Clinician options in the US, however, are limited to tobramycin nebulizer solution (TNS) and aztreonam for inhalation solution (AZLI); in the EU and many other parts of the world, colistimethate and colistimethate dry powder for inhalation (CDPI) are also ...
متن کاملLong-term safety and efficacy of tobramycin in the management of cystic fibrosis
Cystic fibrosis (CF) is a fatal inherited disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene whose mortality is conditioned by a progressive decline in lung function. Bacterial infections play a key role in this decline. Chronic bacterial infection in CF patients varies over time and the presence of Pseudomonas aeruginosa in sputum is a marker of poor prognosi...
متن کاملLung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects.
BACKGROUND Reducing nebulisation times for tobramycin solution for inhalation in cystic fibrosis (CF) may improve compliance. METHODS In this single-dose, open-label, two-way crossover study, 13 subjects (7 CF, 6 healthy) were randomised to receive tobramycin via eFlow rapid or LC Plus jet nebuliser. Drug deposition in the lung using gamma scintigraphic imaging, nebulisation times, pharmacoki...
متن کاملTreatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
BACKGROUND This study assessed treatment satisfaction of cystic fibrosis (CF) patients in a routine clinical setting for tobramycin inhalation powder (TIP), the first dry powder-inhaled antibiotic for Pseudomonas aeruginosa infection. METHODS CF patients aged 6 years or older treated with at least one cycle of TIP completed a web survey on experience with TIP, including the Treatment Satisfac...
متن کاملEconomic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
BACKGROUND Chronic lung infection with Pseudomonas aeruginosa occurs in approximately 50% of patients with cystic fibrosis (CF). This infection further compromises lung function, and significantly contributes to the increased healthcare costs. OBJECTIVES Inhaled tobramycin, used to manage P. aeruginosa infection in CF patients, is available as powder (tobramycin inhalation powder, TIP) and so...
متن کامل